158 related articles for article (PubMed ID: 33423934)
21. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients.
Steiner H; Leonhartsberger N; Stoehr B; Peschel R; Pichler R
Eur Urol; 2013 Jun; 63(6):1013-7. PubMed ID: 23021090
[TBL] [Abstract][Full Text] [Related]
22. Laparoscopic retroperitoneal lymph node dissection for stage I nonseminomatous germ cell testis tumors: the first case series in Iran.
Ziaee SA; Tabibi A; Sharifiaghdas F; Ghahestani SM; Zare S; Samzadeh M
Urol J; 2011; 8(1):27-30. PubMed ID: 21404199
[TBL] [Abstract][Full Text] [Related]
23. Is there still a place for retroperitoneal lymph node dissection in clinical stage 1 nonseminomatous testicular germ-cell tumours? A retrospective clinical study.
Dieckmann KP; Anheuser P; Kulejewski M; Gehrckens R; Feyerabend B
BMC Urol; 2018 Oct; 18(1):95. PubMed ID: 30367648
[TBL] [Abstract][Full Text] [Related]
24. Post-chemotherapy retroperitoneal lymph node dissection in the management of metastatic testis cancer: the 16-year experience in an Irish setting.
Considine S; Heaney R; Conroy R; Thornhill JA
Ir J Med Sci; 2016 Nov; 185(4):901-907. PubMed ID: 26692387
[TBL] [Abstract][Full Text] [Related]
25. Management of patients with clinical stage I or II nonseminomatous germ cell tumors of the testis. Evolving therapeutic options.
Richie JP; Socinsky MA; Fung CY; Brodsky GL; Kalish LA; Garnick MB
Arch Surg; 1987 Dec; 122(12):1443-5. PubMed ID: 2446590
[TBL] [Abstract][Full Text] [Related]
26. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
[TBL] [Abstract][Full Text] [Related]
27. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumor: a large single institution experience.
Hyams ES; Pierorazio P; Proteek O; Sroka M; Kavoussi LR; Allaf ME
J Urol; 2012 Feb; 187(2):487-92. PubMed ID: 22177913
[TBL] [Abstract][Full Text] [Related]
28. Post-chemotherapy laparoscopic retroperitoneal lymph node dissection is feasible for stage IIA/B non-seminoma germ cell tumors.
Nakamura T; Kawauchi A; Oishi M; Ueda T; Shiraishi T; Nakanishi H; Kamoi K; Naya Y; Hongo F; Okihara K; Miki T
Int J Clin Oncol; 2016 Aug; 21(4):791-795. PubMed ID: 26701172
[TBL] [Abstract][Full Text] [Related]
29. Retroperitoneal lymph node dissection for testicular seminomas: population-based practice and survival outcomes.
Patel HD; Joice GA; Schwen ZR; Semerjian A; Alam R; Srivastava A; Allaf ME; Pierorazio PM
World J Urol; 2018 Jan; 36(1):73-78. PubMed ID: 29026972
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
[TBL] [Abstract][Full Text] [Related]
31. Management of patients with low-stage nonseminomatous germ cell testicular cancer.
Stephenson AJ; Sheinfeld J
Curr Treat Options Oncol; 2005 Sep; 6(5):367-77. PubMed ID: 16107240
[TBL] [Abstract][Full Text] [Related]
32. A nomogram for predicting survival and retroperitoneal lymph node dissection treatment in patients with resected testicular germ cell tumors.
Wu Y; Meyers JP; Shi G; Jin Z; Xia J; Gu Y; Qian Q; Hong Y
J Surg Oncol; 2019 Sep; 120(3):508-517. PubMed ID: 31140623
[TBL] [Abstract][Full Text] [Related]
33. [Primary laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ-cell testis tumor].
Castillo OA; Sánchez-Salas R; Secin FP; Campero JM; Foneron A; Vidal-Mora I
Actas Urol Esp; 2011 Jan; 35(1):22-8. PubMed ID: 21256391
[TBL] [Abstract][Full Text] [Related]
34. Comparative Effectiveness of Surveillance, Primary Chemotherapy, Radiotherapy and Retroperitoneal Lymph Node Dissection for the Management of Early Stage Testicular Germ Cell Tumors: A Systematic Review.
Pierorazio PM; Cheaib JG; Patel HD; Gupta M; Sharma R; Zhang A; Tema G; Bass EB
J Urol; 2021 Feb; 205(2):370-382. PubMed ID: 32915080
[TBL] [Abstract][Full Text] [Related]
35. Utilization of retroperitoneal lymph node dissection for testicular cancer in the United States: Results from the National Cancer Database (1998-2011).
Hugen CM; Hu B; Jeldres C; Burton C; Nichols CR; Porter CR; Daneshmand S
Urol Oncol; 2016 Nov; 34(11):487.e7-487.e11. PubMed ID: 27372281
[TBL] [Abstract][Full Text] [Related]
36. Long-term results of laparoscopic retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testicular cancer.
Neyer M; Peschel R; Akkad T; Springer-Stöhr B; Berger A; Bartsch G; Steiner H
J Endourol; 2007 Feb; 21(2):180-3. PubMed ID: 17338618
[TBL] [Abstract][Full Text] [Related]
37. Impact of age on clinicopathological outcomes and recurrence-free survival after the surgical management of nonseminomatous germ cell tumour.
Masterson TA; Carver BS; Abel EJ; Pettus JA; Bosl GJ; Sheinfeld J
BJU Int; 2012 Oct; 110(7):950-5. PubMed ID: 22394608
[TBL] [
